• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

云南省傈僳族人群中药物基因组VIP基因变异的群体遗传差异

Population genetic difference of pharmacogenomic VIP gene variants in the Lisu population from Yunnan Province.

作者信息

Zhang Chan, Jiang Xiaochun, Chen Wanlu, Li Qi, Yun Fubin, Yang Xin, Dai Run, Cheng Yujing

机构信息

Department of Blood Transfusion, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology.

Department of Blood Transfusion, The Third People's Hospital of Yunnan Province, Kunming, Yunnan, China.

出版信息

Medicine (Baltimore). 2018 Dec;97(52):e13674. doi: 10.1097/MD.0000000000013674.

DOI:10.1097/MD.0000000000013674
PMID:30593137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6314765/
Abstract

Individual differences in drug clinical response are related to pharmacogenomics. The genetic variation of drug-metabolizing enzymes, drug receptors, and their downstream protein genes is the main factor causing individual differences in drug response. The genetic backgrounds among different ethnic groups are quite different. In this study, we aimed to detect the distribution difference of genotype frequency in very important pharmacogenetic (VIP) gene variants in the Lisu.Using the chi-squared test, we compared the genotype frequencies of the VIP variants in 105 Lisu people with those in 26 populations from the 1000 Genome project separately. Bonferroni's multiple adjustment was also conducted (P < .05/(26*49)). Moreover, Arlequin v3.5 and Structure v2.3.4 software were used to analyze the genetic distance and genetic structure.There were 9, 9, 11, 12, 11, 11, 9, 17, 13, 13, 16, 5, 3, 5, 3, 4, 17, 14, 16, 17, 16, 10, 13, 12, 10, and 9 single nucleotide polymorphisms that differed in frequency distribution, when Lisu people compared with the 26 populations separately. Only CYP2E1 rs2070676 was different in the Lisu population compared with the 26 groups from the 1000 Genome project. PTGS2 rs5275 and CYP2D6 rs1065852 were different in the Lisu population compared with most of the populations. Additionally, genetic backgrounds of Lisu and Han Chinese in Beijing were closest according to the lowest F-statistics value and resemblance in genetic structures.Our results complete the information of the Lisu population in pharmacogenomics database.

摘要

药物临床反应的个体差异与药物基因组学有关。药物代谢酶、药物受体及其下游蛋白基因的遗传变异是导致药物反应个体差异的主要因素。不同种族群体的遗传背景差异很大。在本研究中,我们旨在检测傈僳族中非常重要的药物遗传学(VIP)基因变异的基因型频率分布差异。我们使用卡方检验,分别将105名傈僳族人的VIP变异基因型频率与千人基因组计划中26个群体的基因型频率进行比较。还进行了Bonferroni多重校正(P <.05/(26*49))。此外,使用Arlequin v3.5和Structure v2.3.4软件分析遗传距离和遗传结构。当傈僳族分别与26个群体比较时,有9、9、11、12、11、11、9、17、13、13、16、5、3、5、3、4、17、14、16、17、16、10、13、12、10和9个单核苷酸多态性的频率分布存在差异。与千人基因组计划的26个群体相比,只有CYP2E1 rs2070676在傈僳族群体中有所不同。与大多数群体相比,PTGS2 rs5275和CYP2D6 rs1065852在傈僳族群体中有所不同。此外,根据最低的F统计值和遗传结构的相似性,傈僳族和北京汉族的遗传背景最为接近。我们的研究结果完善了药物基因组学数据库中傈僳族群体的信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1a9/6314765/14b43eeb54ed/medi-97-e13674-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1a9/6314765/b709e8ab94d7/medi-97-e13674-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1a9/6314765/14b43eeb54ed/medi-97-e13674-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1a9/6314765/b709e8ab94d7/medi-97-e13674-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1a9/6314765/14b43eeb54ed/medi-97-e13674-g004.jpg

相似文献

1
Population genetic difference of pharmacogenomic VIP gene variants in the Lisu population from Yunnan Province.云南省傈僳族人群中药物基因组VIP基因变异的群体遗传差异
Medicine (Baltimore). 2018 Dec;97(52):e13674. doi: 10.1097/MD.0000000000013674.
2
Genetic polymorphisms of pharmacogenomic VIP variants in the Lisu population of southwestern China: A cohort study.中国西南部傈僳族人群药物基因组VIP变异体的遗传多态性:一项队列研究。
Medicine (Baltimore). 2018 Sep;97(38):e12231. doi: 10.1097/MD.0000000000012231.
3
Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China.中国南方壮族人群药物基因组 VIP 变异的遗传变异。
Pharmacogenomics J. 2021 Feb;21(1):60-68. doi: 10.1038/s41397-020-0177-y. Epub 2020 Jul 23.
4
Genetic polymorphisms of very important pharmacogene variants in the Chinese Lisu population.中国傈僳族人群中非常重要的药物基因变异的遗传多态性。
Per Med. 2023 May;20(3):239-249. doi: 10.2217/pme-2022-0117. Epub 2023 Jul 10.
5
Genetic polymorphisms in very important pharmacogenomic variants in the Zhuang ethnic group of Southwestern China: A cohort study in the Zhuang population.中国西南部壮族人群中非常重要的药物基因组学变异的基因多态性:一项壮族人群队列研究。
Medicine (Baltimore). 2018 Apr;97(17):e0559. doi: 10.1097/MD.0000000000010559.
6
Genetic polymorphisms of pharmacogenomic VIP variants in the Yi population from China.中国彝族人群中药物基因组学VIP变异体的基因多态性。
Gene. 2018 Mar 30;648:54-62. doi: 10.1016/j.gene.2018.01.040. Epub 2018 Jan 12.
7
Genetic polymorphisms of pharmacogenomic VIP variants in the Hui population from Ningxia Province of China.中国宁夏回族人群 VIP 药代基因组学变异的遗传多态性。
Funct Integr Genomics. 2023 Mar 17;23(2):85. doi: 10.1007/s10142-023-01021-3.
8
Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China.中国云南省佤族人群药物基因组学 VIP 变异的遗传分析。
BMC Genom Data. 2021 Nov 19;22(1):51. doi: 10.1186/s12863-021-00999-8.
9
Genetic polymorphisms of pharmacogenomic VIP variants in the Lahu population from Yunnan Province.云南省拉祜族人群药物基因组学 VIP 变异体的遗传多态性。
Gene. 2022 Nov 30;844:146825. doi: 10.1016/j.gene.2022.146825. Epub 2022 Aug 19.
10
The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations.景颇族人群中非常重要的药物基因变异体及其潜在临床相关性的研究:与世界人群的比较研究。
Cancer Chemother Pharmacol. 2024 May;93(5):481-496. doi: 10.1007/s00280-023-04638-0. Epub 2024 Feb 1.

引用本文的文献

1
Influence of Metabolic, Transporter, and Pathogenic Genes on Pharmacogenetics and DNA Methylation in Neurological Disorders.代谢、转运体和致病基因对神经疾病中药物遗传学和DNA甲基化的影响。
Biology (Basel). 2023 Aug 22;12(9):1156. doi: 10.3390/biology12091156.
2
Relevance of Gene Variants in Population Genetic Differentiation.基因变异在群体遗传分化中的相关性。
Pharmaceutics. 2022 Nov 16;14(11):2481. doi: 10.3390/pharmaceutics14112481.
3
Genetic Polymorphism of Drug Metabolic Gene and of Five Ethnic Minorities in Heilongjiang Province, Northeast China.

本文引用的文献

1
Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy.CYP2D6 和 CYP2C9 基因多态性与早发型重度子痫前期及拉贝洛尔治疗反应的相关性。
Arch Gynecol Obstet. 2018 Jul;298(1):125-132. doi: 10.1007/s00404-018-4791-8. Epub 2018 May 22.
2
Genetic polymorphisms in very important pharmacogenomic variants in the Zhuang ethnic group of Southwestern China: A cohort study in the Zhuang population.中国西南部壮族人群中非常重要的药物基因组学变异的基因多态性:一项壮族人群队列研究。
Medicine (Baltimore). 2018 Apr;97(17):e0559. doi: 10.1097/MD.0000000000010559.
3
中国东北黑龙江省五个少数民族药物代谢基因的遗传多态性
Pharmgenomics Pers Med. 2021 Nov 30;14:1537-1547. doi: 10.2147/PGPM.S339854. eCollection 2021.
4
Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population.藏族人群中药物基因组VIP变异体的群体遗传差异
Pharmgenomics Pers Med. 2021 Aug 16;14:1027-1040. doi: 10.2147/PGPM.S316711. eCollection 2021.
5
Genetic polymorphisms of pharmacogenomic VIP variants in the Dai population from Yunnan province.云南傣族人群药物基因组 VIP 变异的遗传多态性。
Mol Genet Genomic Med. 2020 Jul;8(7):e1231. doi: 10.1002/mgg3.1231. Epub 2020 Apr 29.
Genetic polymorphisms of pharmacogenomic VIP variants in the Yi population from China.
中国彝族人群中药物基因组学VIP变异体的基因多态性。
Gene. 2018 Mar 30;648:54-62. doi: 10.1016/j.gene.2018.01.040. Epub 2018 Jan 12.
4
The effect of polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis.多态性对亚洲乳腺癌患者辅助性他莫昔芬治疗效果的影响:一项荟萃分析。
Onco Targets Ther. 2017 Nov 13;10:5429-5437. doi: 10.2147/OTT.S149197. eCollection 2017.
5
CYP2E1 Gene Polymorphisms Related to the Formation of Coronary Artery Lesions in Kawasaki Disease.与川崎病冠状动脉病变形成相关的CYP2E1基因多态性
Pediatr Infect Dis J. 2017 Nov;36(11):1039-1043. doi: 10.1097/INF.0000000000001657.
6
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.对于CYP2D6活性降低的患者,增加他莫昔芬剂量可使4-羟基他莫昔芬浓度正常化且不增加毒性。
Oncologist. 2016 Jul;21(7):795-803. doi: 10.1634/theoncologist.2015-0480. Epub 2016 May 25.
7
The population genetics of pharmacogenomics VIP variants in the Sherpa population.夏尔巴人群中药物基因组学VIP变异体的群体遗传学
Drug Metab Pharmacokinet. 2016 Feb;31(1):82-89. doi: 10.1016/j.dmpk.2015.11.007. Epub 2015 Dec 11.
8
Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China.中国西南珞巴族人群中药物基因组学VIP变异体的基因多态性
Int J Clin Exp Pathol. 2015 Oct 1;8(10):13293-303. eCollection 2015.
9
Genetic Polymorphisms Analysis of Pharmacogenomic VIP Variants in Miao Ethnic Group of Southwest China.中国西南苗族人群药物基因组学VIP变异体的基因多态性分析
Med Sci Monit. 2015 Dec 3;21:3769-76. doi: 10.12659/msm.895191.
10
Genetic polymorphisms in very important pharmacogenomic (VIP) variants in the Tibetan population.藏族人群中非常重要的药物基因组学(VIP)变异体的基因多态性。
Genet Mol Res. 2015 Oct 16;14(4):12497-504. doi: 10.4238/2015.October.16.17.